Recent Company News

• 06:32 AM ET Oct 06, 2026
  

  Quoin Pharmaceuticals announces acceptance of QRX003 paper in Dermatology and Therapy ($4.56, 0.00)

• 08:33 AM ET Sep 23, 2026
  

  Quoin Pharmaceuticals initiated buy at Lake Street ($7.01, 0.00)

• 08:32 AM ET Sep 22, 2026
  

  Quoin Pharmaceuticals announces FDA Fast Track Designation for QRX003 for the treatment of peeling skin syndrome ($6.90, 0.00)

• 08:59 AM ET Aug 28, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 28-Aug

• 06:02 AM ET Aug 28, 2026
  

  Quoin Pharmaceuticals announces private placement of 6.3M ADSs and accompanying warrants to purchase up to an aggregate of 3.2M ADSs at a combined purchase price of $4.88 ($5.16, 0.00)

• 08:31 AM ET Aug 14, 2026
  

  Quoin Pharmaceuticals reports Q2 EPS ($1.90) vs FactSet ($1.61) [4 est, ($1.93)-(1.07)] ($6.05, 0.00)

• 08:32 AM ET Jul 09, 2026
  

  Quoin Pharmaceuticals receives FDA IND clearance to initiate Phase 2 study of QRX003 in peeling skin syndrome ($4.72, 0.00)

• 08:34 AM ET Jun 30, 2026
  

  Quoin Pharmaceuticals receives U.S. notice of allowance for patent covering combination treatment for Netherton syndrome ($4.55, 0.00)

• 08:33 AM ET Jun 23, 2026
  

  Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton syndrome ($4.41, 0.00)

• 08:34 AM ET Jun 18, 2026
  

  Quoin Pharmaceuticals completes establishment of Japanese subsidiary to advance commercial readiness for QRX003 ($4.62, 0.00)